Source - SMW
Vectura Group confirmed that a US court had found that one of its patents was valid and infringed upon by three of GlaxoSmithKline's Ellipta products

The jury awarded Vectura $89.7m in damages for the period from August 2016 through December 2018, based on a calculation of 3% of US sales of the products.

Vectura said it expected to seek application of the 3% royalty to the sales of the infringing products through the end of the patent term in mid-2021.

The jury also found that GSK's infringement was willful, Vectura said.

The willfulness finding gave Vectura the right to seek enhanced damages, it said.

GlaxoSmithKline has the option to appeal the decision.

'Although we regret the need to take a longstanding partner to court, we are pleased with the jury's verdict which confirms the validity of our intellectual property and the decision to progress this action with GlaxoSmithKline,' chief executive James Ward-Lilley said.

'We will provide updates on this matter in due course.'